Nasdaq · Biotech stocks database
VALN (Valneva SE) stock: $5.51, $522.8M market cap, $123.4M cash, $601.0M EV, $521.8M fully diluted market cap. Data from Fully Diluted's biotech stocks database.
We are a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. We take a highly specialized and targeted approach, applying our deep expertise across multiple vaccine modalities, focused on providing either first-, best-, or only-in-class vaccine solutions.
Source: 20-F FY2025 via SEC EDGAR
| Cash | $123.4M |
|---|---|
| Debt | $201.6M |
| Net cash | -$78.2M |
| Enterprise value | $601.0M |
| Basic shares | 86.7M shares |
| Fully diluted shares | 94.7M shares |
| Fully diluted market cap | $521.8M |
| Cash per share | $1.42 |
Cash figures as of 2025-12-31. Database snapshot: 2026-11-07.
Cap table as of 2025-12-31.
Loading VALN daily closes…
LB6V (Lyme disease vaccine candidate, partner Pfizer) · Est. May 8, 2027 · guidance midpoint · guided Now